EP Patent

EP2464346A1 — Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder

Assigned to Pulmatrix Inc · Expires 2012-06-20 · 14y expired

What this patent protects

The invention relates to a methods for treating cystic fibrosis, comprising administering an effective amount of a calcium salt formulation to the respiratory tract of an individual with cystic fibrosis. The calcium salt formulation is can be a dry powder formulation.

USPTO Abstract

The invention relates to a methods for treating cystic fibrosis, comprising administering an effective amount of a calcium salt formulation to the respiratory tract of an individual with cystic fibrosis. The calcium salt formulation is can be a dry powder formulation.

Drugs covered by this patent

Patent Metadata

Patent number
EP2464346A1
Jurisdiction
EP
Classification
—
Expires
2012-06-20
Drug substance claim
No
Drug product claim
No
Assignee
Pulmatrix Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.